Recursion Pharmaceuticals Inc
RXRX4.660USD
-0.040-0.85%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
2.29BMarket Cap
LossP/E TTM
More Details of Recursion Pharmaceuticals Inc Company
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology and chemistry to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits, scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate silico hypotheses into validated insights and novel chemistry. Its clinical programs in oncology and rare diseases include REC-617, REC-1245, REC-3565 and REC-4539. Its REC-617 is an orally bioavailable, cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced solid tumors. Its REV102 program targets ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), an enzyme implicated in the pathogenesis of HPP.
Recursion Pharmaceuticals Inc Info
Ticker SymbolRXRX
Company nameRecursion Pharmaceuticals Inc
IPO dateApr 16, 2021
CEOKhan (Najat)
Number of employees840
Security typeOrdinary Share
Fiscal year-endApr 16
Address41S Rio Grande Street
CitySALT LAKE CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code84101
Phone13852690203
Websitehttps://www.recursion.com/
Ticker SymbolRXRX
IPO dateApr 16, 2021
CEOKhan (Najat)
Company Executives of Recursion Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+2381.00%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
142.33K
+3571.00%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
104.85K
-28440.00%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
91.71K
+22016.00%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+11008.00%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
41.59K
+26953.00%
Dr. Christopher Gibson, Ph.D.
Dr. Christopher Gibson, Ph.D.
Chairman of the Board
Chairman of the Board
15.52K
--
Mr. Zachary Bogue, J.D.
Mr. Zachary Bogue, J.D.
Independent Director
Independent Director
9.38K
--
Dr. Blake Borgeson, Ph.D.
Dr. Blake Borgeson, Ph.D.
Independent Director
Independent Director
--
--
Dr. Franziska Michor, Ph.D.
Dr. Franziska Michor, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Dean Y. Li, M.D., Ph.D.
Dr. Dean Y. Li, M.D., Ph.D.
Independent Director
Independent Director
3.20M
+2381.00%
Mr. Zavain Dar
Mr. Zavain Dar
Independent Director
Independent Director
142.33K
+3571.00%
Mr. Ben R. Taylor
Mr. Ben R. Taylor
Chief Financial Officer, President of Recursion UK
Chief Financial Officer, President of Recursion UK
104.85K
-28440.00%
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Dr. Robert M. (Rob) Hershberg, M.D., Ph.D.
Lead Independent Vice Chairman of the Board
Lead Independent Vice Chairman of the Board
91.71K
+22016.00%
Ms. Elaine D. Sun
Ms. Elaine D. Sun
Independent Director
Independent Director
47.56K
+11008.00%
Dr. Najat Khan, Ph.D.
Dr. Najat Khan, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
41.59K
+26953.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United Kingdom
4.07M
78.55%
United States
1.11M
21.45%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.72%
ARK Investment Management LLC
6.52%
BlackRock Institutional Trust Company, N.A.
5.29%
Baillie Gifford & Co.
4.66%
State Street Investment Management (US)
3.55%
Other
72.24%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
7.72%
ARK Investment Management LLC
6.52%
BlackRock Institutional Trust Company, N.A.
5.29%
Baillie Gifford & Co.
4.66%
State Street Investment Management (US)
3.55%
Other
72.24%
Shareholder Types
Shareholders
Proportion
Investment Advisor
37.28%
Investment Advisor/Hedge Fund
10.62%
Venture Capital
5.57%
Sovereign Wealth Fund
2.49%
Individual Investor
2.39%
Research Firm
1.93%
Corporation
1.50%
Hedge Fund
1.47%
Bank and Trust
1.10%
Other
35.64%
Institutional Shareholding
Updated: Mon, Jan 5
Updated: Mon, Jan 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
663
312.05M
60.69%
-8.29M
2025Q3
669
303.20M
58.89%
-18.41M
2025Q2
658
317.16M
74.44%
-11.74M
2025Q1
665
322.62M
81.56%
-7.38M
2024Q4
611
317.29M
80.77%
+25.35M
2024Q3
560
281.65M
104.01%
-6.72M
2024Q2
527
272.94M
105.41%
+14.66M
2024Q1
478
234.97M
104.72%
-10.28M
2023Q4
433
227.80M
110.74%
+18.50M
2023Q3
402
195.18M
97.47%
+1.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
39.71M
7.72%
+3.71M
+10.30%
Sep 30, 2025
ARK Investment Management LLC
33.55M
6.52%
+556.87K
+1.69%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
27.22M
5.29%
+3.29M
+13.75%
Sep 30, 2025
Baillie Gifford & Co.
23.98M
4.66%
-195.12K
-0.81%
Sep 30, 2025
State Street Investment Management (US)
18.27M
3.55%
+7.09M
+63.41%
Sep 30, 2025
SB Global Advisers Ltd
14.67M
2.85%
--
--
Sep 30, 2025
Kinnevik AB
13.43M
2.61%
--
--
Sep 30, 2025
Mubadala Investment Company PJSC
9.64M
1.88%
-3.34M
-25.73%
Dec 18, 2025
MIC Capital Management UK LLP
9.64M
1.88%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
9.62M
1.87%
+1.85M
+23.75%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
ARK Genomic Revolution ETF
5.69%
First Trust Nasdaq AI and Robotics ETF
1.75%
Global X HealthTech ETF
1.73%
AXS Green Alpha ETF
1.36%
ARK Innovation ETF
1.17%
State Street SPDR S&P Biotech ETF
0.95%
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
WisdomTree BioRevolution Fund
0.65%
Direxion Daily S&P Biotech Bull 3X Shares
0.62%
Franklin Genomic Advancements ETF
0.44%
View more
ARK Genomic Revolution ETF
Proportion5.69%
First Trust Nasdaq AI and Robotics ETF
Proportion1.75%
Global X HealthTech ETF
Proportion1.73%
AXS Green Alpha ETF
Proportion1.36%
ARK Innovation ETF
Proportion1.17%
State Street SPDR S&P Biotech ETF
Proportion0.95%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.72%
WisdomTree BioRevolution Fund
Proportion0.65%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.62%
Franklin Genomic Advancements ETF
Proportion0.44%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Recursion Pharmaceuticals Inc?
The top five shareholders of Recursion Pharmaceuticals Inc are:
The Vanguard Group, Inc. holds 39.71M shares, accounting for 7.72% of the total shares.
ARK Investment Management LLC holds 33.55M shares, accounting for 6.52% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 27.22M shares, accounting for 5.29% of the total shares.
Baillie Gifford & Co. holds 23.98M shares, accounting for 4.66% of the total shares.
State Street Investment Management (US) holds 18.27M shares, accounting for 3.55% of the total shares.
The Vanguard Group, Inc. holds 39.71M shares, accounting for 7.72% of the total shares.
ARK Investment Management LLC holds 33.55M shares, accounting for 6.52% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 27.22M shares, accounting for 5.29% of the total shares.
Baillie Gifford & Co. holds 23.98M shares, accounting for 4.66% of the total shares.
State Street Investment Management (US) holds 18.27M shares, accounting for 3.55% of the total shares.
What are the top three shareholder types of Recursion Pharmaceuticals Inc?
The top three shareholder types of Recursion Pharmaceuticals Inc are:
The Vanguard Group, Inc.
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Recursion Pharmaceuticals Inc (RXRX)?
As of 2025Q4, 663 institutions hold shares of Recursion Pharmaceuticals Inc, with a combined market value of approximately 312.05M, accounting for 60.69% of the total shares. Compared to 2025Q3, institutional shareholding has increased by 1.80%.
What is the biggest source of revenue for Recursion Pharmaceuticals Inc?
In FY2025Q3, the -- business generated the highest revenue for Recursion Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
